Manufacturer
Mylan Pharmaceuticals, Inc.
162 drugs, 404 product strengths, 82 recalls on record.
Drugs Mylan Pharmaceuticals, Inc. makes
Atorvastatin+2.4%Generic · 50 makersPharmacies pay from$0.699 open recallsAlbuterol+0.4%Generic · 42 makersPharmacies pay from$5.543 open recallsAmlodipine-2.6%Generic · 33 makersPharmacies pay from$0.3017 open recallsSertraline+0.8%Generic · 42 makersPharmacies pay from$0.852 open recallsGabapentin+4.5%Generic · 72 makersPharmacies pay from$0.667 open recallsPantoprazole+2.7%Generic · 62 makersPharmacies pay from$1.103 open recallsAlprazolam+1.5%Generic · 26 makersPharmacies pay from$0.684 open recallsMethylphenidate-1.0%Generic · 28 makersPharmacies pay from$3.65Unavailable1 open recallPregabalin+5.4%Generic · 38 makersPharmacies pay from$1.341 open recallEsomeprazole-3.4%Generic · 107 makersPharmacies pay from$3.844 open recallsValacyclovir+3.4%Generic · 36 makersPharmacies pay from$6.87Sildenafil+2.3%Generic · 54 makersPharmacies pay from$1.572 open recallsMetformin+2.2%Generic · 65 makersPharmacies pay from$0.44Being discontinued21 open recallsMetoprolol+1.0%Generic · 65 makersPharmacies pay from$0.48Being discontinued9 open recallsPotassium chloride+1.2%Generic · 60 makersPharmacies pay from$2.51Being discontinued2 open recallsPrednisone+0.3%Generic · 39 makersPharmacies pay from$1.11Citalopram+2.3%Generic · 30 makersPharmacies pay from$0.86Cetirizine-4.2%Generic · 146 makersPharmacies pay from$1.365 open recallsLoratadine+3.5%Generic · 145 makersPharmacies pay from$1.641 open recallAllopurinol-1.1%Generic · 39 makersPharmacies pay from$0.94Being discontinuedSpironolactone-0.1%Generic · 35 makersPharmacies pay from$1.28Being discontinued3 open recallsBuspirone-0.8%Generic · 40 makersPharmacies pay from$0.662 open recallsPropranolol-0.6%Generic · 38 makersPharmacies pay from$1.39UnavailableEstradiol-0.5%Generic · 39 makersPharmacies pay from$1.8617 open recallsClonidine-3.4%Generic · 38 makersPharmacies pay from$0.704 open recallsValsartan-0.3%Generic · 26 makersPharmacies pay from$2.42Being discontinued54 open recallsMirtazapine-1.0%Generic · 31 makersPharmacies pay from$1.87Diltiazem+1.6%Generic · 34 makersPharmacies pay from$1.52Being discontinued9 open recallsLevetiracetam-1.9%Generic · 63 makersPharmacies pay from$1.702 open recallsMethotrexate+3.5%Generic · 28 makersPharmacies pay from$3.50Unavailable1 open recallFenofibrate-10.4%Generic · 42 makersPharmacies pay from$2.192 open recallsChlorthalidone-1.6%Generic · 31 makersPharmacies pay from$2.193 open recallsParoxetine+2.3%Generic · 38 makersPharmacies pay from$1.886 open recallsHydrocortisone-0.5%Generic · 212 makersPharmacies pay from$1.45Being discontinued5 open recallsSumatriptan+3.4%Generic · 39 makersPharmacies pay from$7.60Lansoprazole+1.7%Generic · 57 makersPharmacies pay from$3.131 open recallSucralfate-1.9%Generic · 45 makersPharmacies pay from$5.083 open recallsMesalamine-5.0%Generic · 33 makersPharmacies pay from$14.52Being discontinued1 open recallBudesonide+4.1%Generic · 33 makersPharmacies pay from$15.543 open recallsIpratropium+0.3%Generic · 23 makersPharmacies pay from$8.27Clindamycin+2.3%Generic · 52 makersPharmacies pay from$3.14Unavailable13 open recallsFluconazole-3.2%Generic · 31 makersPharmacies pay from$5.73Tretinoin+0.9%Generic · 26 makersPharmacies pay from$9.273 open recallsLatanoprost-0.2%Generic · 15 makersPharmacies pay from$3.932 open recallsMethylprednisolone-4.0%Generic · 25 makersPharmacies pay from$3.03Unavailable5 open recallsMedroxyprogesterone+0.2%Generic · 23 makersPharmacies pay from$3.45Being discontinued5 open recallsNorethindrone+0.2%Generic · 16 makersPharmacies pay from$0.10Liothyronine+1.6%Generic · 15 makersPharmacies pay from$6.17Ticagrelor-4.0%Generic · 21 makersPharmacies pay from$7.29Colchicine-2.6%Generic · 30 makersPharmacies pay from$3.57Lisdexamfetamine+6.8%Generic · 18 makersPharmacies pay from$74.56Limited availability8 open recallsLoperamide+5.2%Generic · 103 makersPharmacies pay from$1.731 open recallKetorolac+3.5%Generic · 57 makersPharmacies pay from$5.11Unavailable12 open recallsValproate+0.7%Generic · 52 makersPharmacies pay from$1.60Unavailable1 open recallEthinyl estradiol / norethindrone-2.9%Generic · 18 makersPharmacies pay from$0.133 open recallsDoxepin+4.3%Generic · 39 makersPharmacies pay from$2.391 open recallDiazepam-6.2%Generic · 38 makersPharmacies pay from$0.63Haloperidol-5.3%Generic · 33 makersPharmacies pay from$2.65Being discontinued9 open recallsVerapamil+8.8%Generic · 31 makersPharmacies pay from$2.15Being discontinued3 open recallsNitroglycerin+1.9%Generic · 32 makersPharmacies pay from$1.96Being discontinued3 open recallsEthinyl estradiol / levonorgestrel+2.4%Generic · 16 makersPharmacies pay from$0.11Carbidopa / levodopa-3.0%Generic · 26 makersPharmacies pay from$2.21Atenolol+1.3%Generic · 30 makersPharmacies pay from$0.66Voriconazole+8.8%Generic · 30 makersPharmacies pay from$25.005 open recallsPrazosin-0.5%Generic · 28 makersPharmacies pay from$2.49Being discontinued9 open recallsTacrolimus+4.1%Generic · 25 makersPharmacies pay from$3.583 open recallsDoxazosin-3.8%Generic · 26 makersPharmacies pay from$1.744 open recallsPhenytoin-0.8%Generic · 25 makersPharmacies pay from$4.31Buprenorphine / naloxone+8.2%Generic · 22 makersPharmacies pay from$16.17Midodrine-3.9%Generic · 25 makersPharmacies pay from$2.321 open recallCarisoprodol+3.1%Generic · 24 makersPharmacies pay from$2.18Dapsone+4.5%Generic · 23 makersPharmacies pay from$13.62Being discontinued4 open recallsAbiraterone+1.8%Generic · 23 makersPharmacies pay from$23.651 open recallEszopiclone+7.3%Generic · 23 makersPharmacies pay from$2.731 open recallHyoscyamine-5.8%Generic · 21 makersPharmacies pay from$4.30Linezolid+2.3%Generic · 23 makersPharmacies pay from$44.22Cimetidine-1.6%Generic · 19 makersPharmacies pay from$6.131 open recallTelmisartan+9.1%Generic · 20 makersPharmacies pay from$3.29Atropine / diphenoxylate+2.9%Generic · 20 makersPharmacies pay from$4.28Rivastigmine-0.9%Generic · 16 makersPharmacies pay from$4.75Being discontinuedFluorouracil+5.2%Generic · 18 makersPharmacies pay from$25.89Sirolimus-1.4%Generic · 17 makersPharmacies pay from$21.381 open recallCyclosporine-0.1%Generic · 14 makersPharmacies pay from$9.934 open recallsDrospirenone / ethinyl estradiol+5.3%Generic · 11 makersPharmacies pay from$0.16Imatinib+3.2%Generic · 15 makersPharmacies pay from$19.33Dabigatran etexilate+0.7%Generic · 13 makersPharmacies pay from$21.469 open recallsAlbuterol / ipratropium-2.8%Generic · 14 makersPharmacies pay from$6.88Armodafinil+1.7%Generic · 11 makersPharmacies pay from$8.88Metolazone+1.0%Generic · 13 makersPharmacies pay from$6.79Benzoyl peroxide / clindamycin-2.0%Generic · 12 makersPharmacies pay from$18.18Clozapine-6.0%Generic · 9 makersPharmacies pay from$7.00Desogestrel / ethinyl estradiol+1.6%Generic · 8 makersPharmacies pay from$0.141 open recallFentanyl-0.4%Generic · 9 makersPharmacies pay from$87.97Unavailable22 open recallsLevalbuterol+2.8%Generic · 11 makersPharmacies pay from$19.121 open recallMacitentanGeneric · 14 makersNo weekly priceMisoprostol-4.1%Generic · 13 makersPharmacies pay from$13.83Formoterol-15.1%Generic · 12 makersPharmacies pay from$64.901 open recallAbacavir+1.2%Generic · 12 makersPharmacies pay from$16.57Hydrochlorothiazide / valsartan-3.2%Generic · 9 makersPharmacies pay from$3.0216 open recallsExemestane-15.7%Generic · 11 makersPharmacies pay from$18.91Risedronate-14.6%Generic · 8 makersPharmacies pay from$5.88Scopolamine-2.6%Generic · 11 makersPharmacies pay from$50.67Travoprost+3.7%Generic · 11 makersPharmacies pay from$21.76Being discontinuedAcamprosate-0.6%Generic · 11 makersPharmacies pay from$17.581 open recallTamoxifen-0.8%Generic · 10 makersPharmacies pay from$3.96Diclofenac / misoprostol+8.6%Generic · 9 makersPharmacies pay from$23.25Difluprednate-6.3%Generic · 10 makersPharmacies pay from$45.37Ambrisentan-9.8%Generic · 10 makersPharmacies pay from$217Amlodipine / atorvastatin-3.3%Generic · 5 makersPharmacies pay from$23.55Bisoprolol / hydrochlorothiazide-0.6%Generic · 9 makersPharmacies pay from$6.571 open recallPitavastatin+1.5%Generic · 8 makersPharmacies pay from$25.105 open recallsColestipol-0.7%Generic · 9 makersPharmacies pay from$19.60Dexlansoprazole+1.4%Generic · 8 makersPharmacies pay from$110Eletriptan+1.0%Generic · 8 makersPharmacies pay from$47.67Glucagon-12.8%Generic · 8 makersPharmacies pay from$1341 open recallSulfasalazine-0.3%Generic · 9 makersPharmacies pay from$5.95Bromocriptine+1.1%Generic · 8 makersPharmacies pay from$48.811 open recallCabergoline-0.5%Generic · 9 makersPharmacies pay from$38.68Eplerenone+7.6%Generic · 8 makersPharmacies pay from$9.94Ethosuximide+7.7%Generic · 8 makersPharmacies pay from$7.87
Recalls
Class IIOngoingSep 9, 2026Carton label: Mycophenolate Mofetil for injectionFailed Dissolution SpecificationsMylan Pharmaceuticals Inc · D-0830-2026Class IIOngoingSep 9, 2026Prasugrel TabletsFailed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteriaMylan Pharmaceuticals Inc · D-0839-2026Class IIOngoingAug 26, 2026Acamprosate CalciumFailed Dissolution SpecificationsMylan Pharmaceuticals Inc · D-0774-2026Class IIOngoingAug 5, 2026Mycophenolate Mofetil for Injection USPPresence of precipitateMylan Pharmaceuticals Inc · D-0734-2026Class IIOngoingMar 11, 2026AmnesteemFailed Dissolution SpecificationsMylan Pharmaceuticals Inc · D-0399-2026Class IIOngoingMar 26, 2025Prasugrel TabletsFailed Dissolution Specifications - low dissolution resultsMylan Pharmaceuticals Inc · D-0280-2025Class ITerminatedAug 3, 2022Insulin GlargineLabeling: Missing label: Label missing from some prefilled pens.Mylan Pharmaceuticals Inc · D-1292-2022Class ITerminatedMay 4, 2022Insulin GlargineLabeling: Missing label on the vialMylan Pharmaceuticals Inc · D-0845-2022Class IITerminatedApr 27, 2022Rifampin for InjectionFailed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.Mylan Pharmaceuticals Inc · D-0774-2022Class IITerminatedApr 13, 2022Travoprost Ophthalmic SolutionSubpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related...Mylan Pharmaceuticals Inc · D-0748-2022Class IITerminatedFeb 2, 2022Proctofoam HCcGMP deficienciesMylan Pharmaceuticals Inc · D-0452-2022Class ITerminatedJan 26, 2022SemgleeLabeling: Missing Label: label missing from some Semglee prefilled pens.Mylan Pharmaceuticals Inc · D-0462-2022Class IIITerminatedOct 28, 2020Candesartan Cilexetil and Hydrochlorothiazide TabletsOut-of-specification organic impurity results obtained during routine stability testing.Mylan Pharmaceuticals Inc. · D-0049-2021Class IIITerminatedApr 1, 2020Tacrolimus CapsulesPresence of foreign tablet/capsule - Potential presence of commingled one Tacrolimus 1 mg capsule in 5 mg bottles.Mylan Pharmaceuticals Inc. · D-1057-2020Class IITerminatedMar 25, 2020Sotalol HCL TabletsPresence of particulate matter. presence of metal particles.Mylan Pharmaceuticals Inc. · D-1031-2020Class IITerminatedJan 29, 2020Nizatidine CapsulesCGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.Mylan Pharmaceuticals Inc. · D-0791-2020Class IITerminatedJan 29, 2020Nizatidine CapsulesCGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.Mylan Pharmaceuticals Inc. · D-0792-2020Class IITerminatedNov 13, 2019Alprazolam TabletsPresence of Foreign SubstanceMylan Pharmaceuticals Inc. · D-0186-2020Class IITerminatedNov 6, 2019Prasugrel Tablets 5 mgFailed Dissolution Specification: Low out of specification dissolution results.Mylan Pharmaceuticals Inc. · D-0155-2020Class IIITerminatedSep 18, 2019Gatifloxacin Ophthalmic Solution 0.5%Failed Impurities/Degradation Specifications:OOS for unknown impurity.Mylan Pharmaceuticals Inc. · D-1848-2019Class IIITerminatedFeb 27, 2019Diltiazem HCl Extended-Release CapsulesFailed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testingMylan Pharmaceuticals Inc. · D-0506-2019Class IITerminatedFeb 13, 2019DymistaDefective Container: Potential for broken glass in the neck area of the glass bottles.Mylan Pharmaceuticals Inc. · D-0424-2019Class IITerminatedFeb 6, 2019Fexofenadine HCl TabletsFailed Impurities/Degradation Specifications: Related compound results obtained during routine stability testing was slightly elevated above specification.Mylan Pharmaceuticals Inc. · D-0428-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0311-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0312-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0313-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0314-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0315-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0316-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0317-2019
About Mylan Pharmaceuticals, Inc.
No comments yet. Questions, tips, what worked for you - start the conversation.